|
Real-time Estimate
Cboe Europe
18:36:03 19/11/2026 +03
|
5-day change | 1st Jan Change | ||
| 1,832.75 GBX | -1.36% |
|
-3.42% | +0.63% |
| 03:46pm | Pharma sector doubles down on AI to slash costs, timelines | RE |
| 02:22pm | GSK's Velzatinib granted orphan drug designation in Japan for GIST | AN |
| Market Cap | 74.49B 97.88B 89.27B 82.54B 140B 9,147B 146B 997B 394B 4,937B 367B 360B 15,590B | P/E 2026 * |
15.1x | P/E 2027 * | 12x |
|---|---|---|---|---|---|
| Enterprise Value | 96.38B 127B 116B 107B 182B 11,835B 189B 1,290B 510B 6,388B 475B 465B 20,171B | EV / Sales 2026 * |
2.85x | EV / Sales 2027 * | 2.66x |
| Free-Float |
94.95% | Yield 2026 * |
3.74% | Yield 2027 * | 4.03% |
| Markets | Quality | ||
|---|---|---|---|
London S.E.
| GSK | Delayed | |
| GSK | Real-time | ||
| GS71 | Real-time | ||
| GS71 | Delayed | ||
| GS71 | Real-time | ||
| GLAXF | Delayed | ||
| GS71 | Delayed | ||
| GS71 | Delayed | ||
| GS71 | End-of-day quote |
Last Transcript: GSK plc
| 1 day | -1.35% | ||
| 1 week | -3.42% | ||
| Current month | -1.02% | ||
| 1 month | -1.02% | ||
| 3 months | -4.18% | ||
| 6 months | -3.47% | ||
| Current year | +0.63% |
| 1 week | 1,820.5 | 1,950 | |
| 1 month | 1,783.5 | 1,950 | |
| Current year | 1,690 | 2,282 | |
| 1 year | 1,690 | 2,282 | |
| 3 years | 1,242.5 | 2,282 | |
| 5 years | 1,242.5 | 3,408.16 | |
| 10 years | 1,242.5 | 3,408.16 |
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | 52 | 01/01/2026 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 01/05/2023 |
James Ford
CMP | Compliance Officer | - | 01/08/2018 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | 52 | 06/05/2026 |
Hal Barron
BRD | Director/Board Member | 64 | 01/01/2018 |
Jonathan Symonds
CHM | Chairman | 67 | 01/09/2019 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 10/22/26 A | Buy | Executive/Senior Manager | 9 | 0.0000% | ||
| 10/13/26 A | Buy | Executive/Senior Manager | 352 | 0.0000% | ||
| 10/13/26 A | Buy | Compliance Officer | 326 | 0.0000% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -1.36% | -3.42% | +3.58% | +30.40% | 97.88B | ||
| -1.97% | -4.16% | +30.32% | +128.90% | 1,232B | ||
| -2.14% | -5.86% | +31.80% | +78.05% | 656B | ||
| -1.06% | -3.86% | +21.54% | +104.67% | 506B | ||
| -0.81% | -1.35% | +29.27% | +69.09% | 382B | ||
| -2.17% | -8.15% | +42.00% | +31.45% | 340B | ||
| -2.70% | -4.47% | +25.44% | +52.14% | 294B | ||
| -1.69% | -3.43% | -1.06% | +33.11% | 278B | ||
| -0.78% | -5.40% | +29.04% | +66.52% | 240B | ||
| -1.30% | -0.22% | +30.85% | +120.51% | 210B | ||
| Average | -1.60% | -2.23% | +24.28% | +71.48% | 424B | |
| Weighted average by Cap. | -1.71% | -2.65% | +27.28% | +87.06% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 33.83B 44.46B 40.55B 37.49B 63.72B 4,155B 66.23B 453B 179B 2,242B 167B 163B 7,081B | 35.28B 46.36B 42.28B 39.09B 66.44B 4,332B 69.06B 472B 187B 2,338B 174B 170B 7,383B |
| Net income | 4.92B 6.46B 5.89B 5.45B 9.26B 604B 9.63B 65.81B 26.02B 326B 24.24B 23.74B 1,029B | 6.11B 8.03B 7.32B 6.77B 11.51B 750B 11.96B 81.76B 32.32B 405B 30.12B 29.49B 1,279B |
| Net Debt | 21.89B 28.77B 26.24B 24.26B 41.23B 2,688B 42.85B 293B 116B 1,451B 108B 106B 4,582B | 19.18B 25.2B 22.98B 21.25B 36.12B 2,355B 37.54B 257B 101B 1,271B 94.54B 92.56B 4,014B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 19/11/26 | GBX 1,835.00 | -1.24% | 1,244,362 |
| 18/11/26 | GBX 1,858.00 | -0.59% | 4,360,879 |
| 17/11/26 | GBX 1,869.00 | -3.14% | 7,867,700 |
| 16/11/26 | GBX 1,929.50 | +0.94% | 3,702,287 |
| 13/11/26 | GBX 1,911.50 | +0.55% | 3,101,289 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- GSK Stock
Select your edition
All financial news and data tailored to specific country editions

















